Press releases

Press releases

27 September 2014  - Paris (France)

Ipsen presents preliminary results of exploratory proof-of-concept study with tasquinimod in four advanced tumor types at the ESMO 2014 Congress

01 September 2014  - Paris (France)

Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe

29 August 2014  - Paris (France)

Ipsen: 2014 half-year results and 2014 objectives

27 August 2014  - Basking Ridge (USA)

Ipsen North America Announces Second Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2014

17 July 2014  - Paris (France)

New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors

11 July 2014  - Paris (France)

Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe

01 July 2014  - Paris (France)

Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

04 June 2014  - Paris (France)

Ordinary Shareholders’ Meeting of IPSEN S.A. held on 4 June 2014

13 May 2014  - Paris (France)

Ipsen announces a step forward in the resupply of Increlex® in the U.S.

30 April 2014  - Paris (France)

Ipsen’s first quarter 2014 sales